4.7 Article

NFE2L2 and STAT3 Converge on Common Targets to Promote Survival of Primary Lymphoma Cells

Journal

Publisher

MDPI
DOI: 10.3390/ijms241411598

Keywords

PEL; STAT3; NRF2; HSPs; DDR; p62; SQSTM1; autophagy; c-Myc

Ask authors/readers for more resources

NFE2L2 and STAT3 are pro-survival molecules involved in the pathogenesis of PEL. Their simultaneous inhibition impairs the survival of PEL cells by regulating multiple pro-survival pathways. This study suggests that targeting NFE2L2 and STAT3 may be a potential therapeutic strategy for PEL, which has poor response to chemotherapy.
NFE2L2 and STAT3 are key pro-survival molecules, and thus, their targeting may represent a promising anti-cancer strategy. In this study, we found that a positive feedback loop occurred between them and provided evidence that their concomitant inhibition efficiently impaired the survival of PEL cells, a rare, aggressive B cell lymphoma associated with the gammaherpesvirus KSHV and often also EBV. At the molecular level, we found that NFE2L2 and STAT3 converged in the regulation of several pro-survival molecules and in the activation of processes essential for the adaption of lymphoma cells to stress. Among those, STAT3 and NFE2L2 promoted the activation of pathways such as MAPK3/1 and MTOR that positively regulate protein synthesis, sustained the antioxidant response, expression of molecules such as MYC, BIRC5, CCND1, and HSP, and allowed DDR execution. The findings of this study suggest that the concomitant inhibition of NFE2L2 and STAT3 may be considered a therapeutic option for the treatment of this lymphoma that poorly responds to chemotherapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available